GlaxoSmithKline is reporting a shortage in supply of the migraine medication Imitrex Nasal Spray (sumatriptan). The shortage is due to the lack of active pharmaceutical ingredient and affects both the 5mg and the 20mg nasal spray presentations.
Imitrex Nasal spray is indicated for the acute treatment of migraine with or without aura in adults. Sumatriptan is believed to exert its therapeutic effects in the treatment of migraine headaches through agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which results in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
The company expects supply of the nasal spray to be unavailable until February 2016. The FDA is currently not reporting a shortage for the oral tablet or subcutaneous injection formulations of Imitrex.
For more information visit FDA.gov.